Abstract: The present invention relates to the technical field of pharmaceuticals, and particularly to a PDE9 inhibitor compound of formula (I) or a pharmaceutically acceptable salt, an isomer, a deuterated compound, a metabolite or a prodrug thereof. The present invention also relates to pharmaceutical formulations, pharmaceutical compositions and use thereof. X1, X2, X3, X4, R1, R2, ring A, L and m are as defined in the specification. The compound of the present invention can be used in the manufacture of a medicament for treating or preventing a PDE9-mediated related disease.

Abstract: To support packet-based call, a first base station (102, 104) receives, by processing hardware, an indication of whether a user device supports packet-based video over a certain RAT (2302). When the processing hardware at the first base station determines (2304), based on the received indication, that the first base station supports packet-based video over the certain RAT, the base station configures radio resources for establishing a new packet-based video call with the user device over the certain RAT (2306), or hands over an existing packet-based video call, established between the first base station and the user device, to a second base station that operates according to the certain RAT (2308).

Abstract: The present invention relates to the technical field of pharmaceuticals. Specifically, the present invention relates to a halo-allylamine compound, or a pharmaceutically acceptable salt, an ester, a stereoisomer or a tautomer thereof, and a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, and use in preventing and/or treating a disease related to or mediated by the SSAO/VAP-1 protein, wherein R1, R2, R3, R4, R5, R6, L1 and Cy1 are defined in the specification.

Abstract: Provided by the present invention is a novel quinoline derivative inhibitor, which has a structure represented by the following general formula (I). The compound of the present invention may selectively inhibit the TAM family of tyrosine kinases/and CSF1R kinase, and may be used for the treatment and/or prevention of diseases mediated by the abnormal expression of TAM family kinases/and CSF1R kinase receptors and/or ligands thereof. Furthermore, the compound of the present invention may be used to treat and/or prevent related diseases caused by NTRK, more specifically, said compound may be used for the treatment and/or prevention of drug-resistant related diseases caused by NTRK mutations. The definitions of each group are as shown in the description.

Abstract: The present invention belongs to the field of medical technology. Particularly, the present invention relates to a compound shown in formula (I), a pharmaceutically acceptable salt thereof, and a stereoisomer of the same. X, Y, Z, R1, R2, R3, R1a, R2a, m, and n are as defined in the specification. The present invention also relates to pharmaceutical preparations and pharmaceutical compositions of these compounds and a use thereof in preparing a drug for treating a related disease mediated by abnormal indoleamine 2,3-dioxygenase (IDO).

Abstract: The present invention provides a novel inhibitor compound of general formula (I), exhibiting excellent kinase inhibitor activity. The compound of the present invention can be used to prevent and/or treat diseases mediated by abnormal expression of TAM family kinase receptors and/or ligands thereof. In addition, the compound of the present invention can also target CSF1R kinase, and thus can be used to prevent and/or treat diseases mediated by abnormal expression of TAM family kinase receptors and/or CSF1R kinase receptors and/or ligands thereof.

Abstract: The present invention falls within the technical field of medicine, and in particular relates to PDE9 inhibitor compounds as shown in formula (I) or pharmaceutically acceptable salts or stereoisomers thereof, and also relates to pharmaceutical preparations and pharmaceutical compositions of the compounds and the uses thereof. X1, X2, X3, X4, R1, R2, ring A, L and m are as defined in the description. The compounds can be used to prepare drugs for treating or preventing related diseases mediated by PDE9.

Abstract: The present invention relates to a method for treating a cancer mediated by abnormality of multi-kinases, comprising administrating a compound as represented by formula (I) or a pharmaceutically acceptable salt and stereoisomer thereof, wherein R1, R2, X, Y, P, W, and Ar are as defined in the description. Also provided is a method for treating a cancer mediated by abnormality of multi-kinases, comprising administrating a crystal form I of a compound 4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-b]pyrido[4,3-e][1,4]diazepin-8-yl)morpholine, wherein in an X-ray powder diffraction pattern of crystal form I, there are characteristic peaks at 7.4±0.2°, 17.9±0.2°, 18.9±0.2°, 19.4±0.2°, 21.5±0.2°, and 23.7±0.2°.

Abstract: A user device (UE) receives, from a source base station while the user device is operating in a source cell of the source base station, a conditional handover configuration providing information for user device operation within a candidate target cell of a candidate base station, and a corresponding condition for handing over to the candidate target cell of the candidate base station (1202). In some implementations, prior to determining that the condition is satisfied, the UE receives, from the source base station, a handover command message for immediate handover to a target base station (1204), and after receiving the handover command message, releases the conditional handover configuration (1206) and performs an immediate handover to the target base station (1208).

Abstract: A fiber attachment structure may comprise a monolithic platform structure having a first trench and a second trench to segment the monolithic platform structure into a chip mount area, a first island, and a second island. A laser chip may be mounted directly on the chip mount area and an optical fiber may be mounted on the first island by a first adhesive joint and on the second island by a second adhesive joint. For example, in some implementations, the first adhesive joint may include a first quantity of adhesive material attaching the optical fiber to the first island at a position at which a tip of the optical fiber is aligned with an output facet of the laser chip, and the second adhesive joint may include a second quantity of the adhesive material to mechanically secure the optical fiber to the second island.

Abstract: The present invention belongs to the pharmaceutical technical field, and specifically relates to a haloallylamine compound represented by formula I, a pharmaceutically acceptable salt, an ester or a stereoisomer thereof, R1, R2, R3, R4, R5, R6, L1, Cy1, R7 are defined as in the specification; the present invention also relates to pharmaceutical preparations and pharmaceutical compositions containing these compounds, and their use in preventing and/or treating the SSAO/VAP-1 protein-related or SSAO/VAP-1 protein-mediated disease.

Abstract: A fiber attachment structure may comprise a monolithic platform structure having a first trench and a second trench to segment the monolithic platform structure into a chip mount area, a first island, and a second island. A laser chip may be mounted directly on the chip mount area and an optical fiber may be mounted on the first island by a first adhesive joint and on the second island by a second adhesive joint. For example, in some implementations, the first adhesive joint may include a first quantity of adhesive material attaching the optical fiber to the first island at a position at which a tip of the optical fiber is aligned with an output facet of the laser chip, and the second adhesive joint may include a second quantity of the adhesive material to mechanically secure the optical fiber to the second island.

Abstract: The present invention falls within the technical field of medicine, and in particular relates to PDE9 inhibitor compounds as shown in formula (I) or pharmaceutically acceptable salts or stereoisomers thereof, and also relates to pharmaceutical preparations and pharmaceutical compositions of the compounds and the uses thereof. X1, X2, X3, X4, R1, R2, ring A, L and m are as defined in the description. The compounds can be used to prepare drugs for treating or preventing related diseases mediated by PDE9.

Abstract: The present invention relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt and stereoisomer thereof, wherein R1, R2, X, Y, P, W, and Ar are as defined in the description. The compound of formula (I) of the present invention can be used in the preparation of a drug for treating cancers mediated by abnormality of multi-kinases. Also provided is a crystal form I of a compound 4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-b]pyrido[4,3-e][1,4]diazepin-8-yl)morpholine, wherein in an X-ray powder diffraction pattern of crystal form I, there are characteristic peaks at 7.4±0.2°, 17.9±0.2°, 18.9±0.2°, 19.4±0.2°, 21.5±0.2°, and 23.7±0.2°.

Abstract: The present invention relates to the technical field of pharmaceuticals, and particularly to a peptidylarginine deiminase (PAD4) inhibitor compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer and tautomer thereof, and pharmaceutical composition, pharmaceutical formulation and use thereof. X, Y, R1, R2, R3, R4, R5, R7, R8, R9, ring B and m are defined in the specification. The compound disclosed herein has an inhibitory effect on peptidylarginine deiminase (PAD4), and can be used to treat a variety of diseases, such as rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, multiple sclerosis, cystic fibrosis, cancer, cutaneous lupus erythematosus, asthma and psoriasis.

Abstract: The present invention belongs to the technical field of medicine, and particularly relates to a compound represented by Formula I, a pharmaceutically acceptable salt thereof, and a stereoisomer thereof, R4, R4?, R5, R5?, R6, R7, R1a, R2a, m, n, t1, and t2 are as defined in the description; the present invention further relates to a Crystalline Form of the compound represented by Formula I, and the present invention also relates to a pharmaceutical preparation, a pharmaceutical composition, a preparation method of these compounds and Crystalline Forms thereof, as well as a use thereof in manufacture of a medicament for treating a related disease mediated by abnormality of indoleamine 2,3-dioxygenase (IDO).

Abstract: The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts are useful in combination with beta-lactam antibiotics, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3, R4, R5 and R6 are described herein.

Abstract: Provided are an irreversible inhibitor of a fibroblast growth factor receptor (FGFR) as indicated by formula I, a pharmaceutically acceptable salt, a stereoisomer, a pharmaceutical preparation, a pharmaceutical composition and an application thereof. R1, R2, R3, R4, ring A, Ar, ring B and warhead are as defined in the specification. The compound has high-efficiency and high-selectivity inhibition of a fibroblast growth factor receptor and can be applied to treatment of abnormal FGF/FGFR-mediated diseases, in particular the treatment of cancers.

Abstract: In a base station central unit (CU) coupled to one or more base station distributed units (DUs), a base station CU determines that a UE should perform a reconfiguration with sync procedure (1204). The base station CU transmits, to a base station DU, an indication that the UE should perform a reconfiguration with sync procedure (1204). The base station CU then receives, in response to the indication, a cell group configuration IE including a reconfiguration with synchronization IE (1208), and transmits, to the base station DU, a message including the cell group configuration IE, to be forwarded to the UE (1210).

Abstract: The present invention belongs to the field of medical technology. Particularly, the present invention relates to a compound shown in formula (I), a pharmaceutically acceptable salt thereof, and a stereoisomer of the same. X, Y, Z, R1, R2, R3, R1a, R2a, m, and n are as defined in the specification. The present invention also relates to pharmaceutical preparations and pharmaceutical compositions of these compounds and a use thereof in preparing a drug for treating a related disease mediated by abnormal indoleamine 2,3-dioxygenase (IDO).